Used as a key intermediate in the synthesis of antiviral agents, particularly in the production of sofosbuvir, a nucleoside analog for treating Hepatitis C virus (HCV). Its structure supports the development of compounds that inhibit viral replication by mimicking natural nucleosides, thereby interfering with viral RNA synthesis via the HCV NS5B RNA polymerase.

The silyl protecting group (tert-butyldimethylsilyl, TBS) on the 4-hydroxy position enhances molecular stability and reaction selectivity during multi-step organic synthesis. Additionally, the 3-fluoro substitution improves oral absorption, reduces enzymatic degradation, and extends the biological half-life, making it suitable for developing highly effective prodrugs with low dosing frequency.